In a Portland Business Journal story about the death of precision medicine advocate, OHSU Knight Cancer Institute supporter and former Intel exec Bryce Olson, Brian Druker, M.D., says: “Bryce was a passionate advocate for matching cancer patients to the treatments most likely to work against their tumor through DNA sequencing. He boiled this field of precision oncology down to two words: ‘Sequence Me.’ His voice will be missed, but his message will not be forgotten.”

A KFF Health News story highlights a recent study led by OHSU revealing that adolescents are rarely offered medication to treat opioid use disorder in U.S. residential treatment facilities. Caroline King, M.D., Ph.D., says, “I’m not sure if inhumane is too strong of a word. Offering nothing, offering no additional medication, even nausea medication or really basic things, is really a travesty.”

This story highlights a recent study led by OHSU revealing that adolescents are rarely offered medication to treat opioid use disorder in U.S. residential treatment facilities. Caroline King, M.D., Ph.D., says, “I’m not sure if inhumane is too strong of a word. Offering nothing, offering no additional medication, even nausea medication or really basic things, is really a travesty.”

OHSU is ranked as the top hospital in Oregon for 2023-24.

OHSU is ranked as the top hospital in Oregon for 2023-24.

George Thomas, M.D., is named an advisory board member to Auron Therapeutics, platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity.

A nationwide clinical trial led by Christopher W. Ryan, M.D., tests drug everolimus in treating kidney cancer.

New research reveals a promising treatment in stopping the progression of amyotrophic lateral sclerosis. Senior author Bahareh Ajami, Ph.D., says, “At this point, we cannot say it’s a cure but it’s a very interesting start. It may be similar to what immunotherapy did for cancer or will do for Alzheimer’s by targeting immune cells."

New research reveals a promising treatment in stopping the progression of amyotrophic lateral sclerosis. Senior author Bahareh Ajami, Ph.D., says, “At this point, we cannot say it’s a cure but it’s a very interesting start. It may be similar to what immunotherapy did for cancer or will do for Alzheimer’s by targeting immune cells."

The police bureau has been conducting targeted stings over the past two years, but recently refined its methods with help from Oregon Health & Science University researchers.